**Translational research**

**Neuroendocrine models of social anxiety disorder**

Jack van Honk, PhD; Peter A. Bos, PhD; David Terburg, PhD; Sarah Heany, MSc; Dan J. Stein, MD, PhD

---

**Introduction**

Humans are one of nature’s social species. Like other primates, we have evolved to display a range of affiliative and social emotions and behaviors. While affiliative experiences may be rewarding, social situations and hierarchies may also be associated with negative affects such as anxiety. Given the centrality of affiliative and social concerns in human life, the high prevalence of social anxiety disorder (SAD) is not surprising. SAD is a highly prevalent and disabling disorder with key behavioral traits of social fearful-ness, social avoidance, and submissiveness. Here we argue that hormonal systems play a key role in mediating social anxiety, and so may be important in SAD. Hormonal alterations, often established early in development through the interaction between biological and psychological factors (e.g., genetic predisposition x early trauma), predispose to socially fearful, avoidant, and submissive behavior. However, whereas gene variants and histories of trauma persist, hormonal systems can be remodeled over the course of life. Hormones play a key role during the periods of all sensitive developmental windows (i.e., prenatal, neonatal, puberty, aging), and are capable of opening up new developmental windows in adulthood. Indeed, the developmental plasticity of our social brain, and thus of social behavior in adulthood, critically depends on steroid hormones such as testosterone and peptide hormones such as oxytocin. These steroid and peptide hormones in interaction with social experiences may have potential for reprogramming the socially anxious brain. Certainly, single administrations of oxytocin and testosterone in humans reduce socially fearful, avoidant, and submissive behavior. Such work may ultimately lead to new approaches to the treatment of SAD.
lence of social anxiety is not surprising.\(^1\) Furthermore, it is not surprising that social anxiety disorder (SAD) is accompanied by significant distress and functional impairment.\(^2\)

Behavioral inhibition, characterized by socially fearful and avoidant behavior, is both a feature of SAD and a key predictor for the development of this condition.\(^3\) Both in daily life and in experimental work, such social fear and avoidance in SAD manifests in terms of blushing, as well as avoidant or submissive responses to the eye gazes of others. Blushing and gaze aversion in SAD are arguably a pathological manifestation of an evolutionarily evolved submissive response that appears in primate dominance encounters.\(^4\) While rodents dominate by means of aggression, in primates subordinates avert their gaze when challenged by the threat stare of the dominant animal, so allowing the social hierarchy to be regulated nonaggressively.\(^5,7\)

In SAD, however, such social adaptations seem to have gone awry and socially fearful, avoidant, and submissive behaviors are generalized to all of human social interaction. Animal research has established a pivotal role for the neuropeptide oxytocin (OXT) and the steroid testosterone (T) in the development and adaptive preservation of social hierarchies.\(^8,9\) Such work, as well as placebo-controlled studies with single administrations of OXT and T in humans, leads to the hypothesis that imbalances in OXT and T systems may contribute to the pathogenesis of SAD.

**Oxytocin and testosterone**

In many species, including humans, the peptide hormone OXT and the steroid hormone T play a key role in the development and execution of social-emotional behavior, both in males and in females. Depending on the relevant social context and environment, these social hormones act via, and interact with, all the main neurotransmitter systems (that is, the serotonergic, noradrenergic, and dopaminergic systems). The other key social hormone systems, the estrogen and the vasopressin systems, depend critically on T, as the most important estrogen, estradiol, is a metabolite of T, and vasopressin depends on T for its gene expression.

Since OXT depends on estradiol for its gene expression, all of our social behavior is ultimately based upon T, a hormone that is ironically associated with antisocial behavior in some folk psychologies.\(^10\) Although OXT and T possess opposite behavioral properties, for example in the domain of cognitive empathy,\(^11,12\) they are certainly not antagonistic hormones in their effects on brain and behavior. On the contrary, the OXT and T systems are intrinsically intertwined, jointly critical for the execution of sexual behavior, and have important and seemingly complementary anxiolytic/fear-reducing properties.

OXT and T act, directly or indirectly, via other hormone or neurotransmitter systems, on all social-affective brain systems including the orbitofrontal cortex (OFC), anterior cingulate cortex (ACC), amygdala, ventral striatum, hypothalamus, and brain stem. However, depending on biological predisposition, early adversity (for example, abuse or neglect) can disorganize the expression of social-emotional behaviors by creating imbalances in hormonal systems, and especially in the OXT and T systems. These hormonal imbalances have negative effects on the social-emotional brain and can produce socially fearful, avoidant, and submissive behaviors, with insensitivity for social rewards.

Early-life social experiences shape the expression of adult social behaviors via neuropeptide and steroid systems, and especially the OXT and T systems, which among others organize the expression of fear and aggression, and related approach and avoidance behaviors. Notably, changes in the production and secretion of OXT and T in response to social events, and changes in the social brain’s sensitivity to these hormones, are fundamental mechanisms by which social experience affects later social behaviors. Furthermore, the social-emotional behaviors governed by the OXT and T systems seem to play a major role in SAD.

There is some evidence that OXT and T levels measured in plasma or saliva are lowered in SAD.\(^13,14\) However, saliva and plasma measures only coarsely reflect brain OXT and T, as OXT does not cross the blood-brain barrier, and T is produced not only by the gonads and adrenals, but also is a neurosteroid in the brain that is not measurable peripherally.\(^15\) What makes OXT and T of specific interest to SAD are placebo-controlled OXT and T administration studies in humans, which suggest that these hormones can alleviate the core behavioral hallmarks of SAD (social fearfulness, avoidance, submissiveness), and increase sensitivity to social rewards, as described in more detail below.

The robust evidence for acute behavioral plasticity in the OXT and T systems, with transient development
of new social behaviors in adulthood in response to single administrations of OXT and T, potentially opens up significant therapeutic opportunities, particularly in light of one of the important scientific discoveries of recent decades, that of adult neuroplasticity. Adult neuroplasticity refers to structural changes in brain regions and rewiring of brain pathways in adulthood, and social experiences. OXT and T not only develop and execute our social-emotional behavior,16 but they also are key players in adult neuroplasticity.17–19 Importantly, OXT and T are able to open up new developmental windows in adulthood, and on these windows social experiences (and thus psychosocial interventions) can potentially act to bring lasting change (Figure 1).

Effects of oxytocin and testosterone on fear and anxiety

In rodent research, the anxiolytic or (social) fear-reducing properties of OXT and T have been well established.20,21 T elevations in rats increase social exploration, while decreasing anxiety, punishment, and avoidance.22–24 Compared with intact male rats and/or gonadectomized rats with replacement hormone, gonadectomized rats show more anxiety, fear, and freezing behavior on a large variety of tasks.25–28 Finally, other testosterone deficits also result in enhanced fear responses.28

Importantly, anxiolytic/fear-reducing effects of OXT are often observed in social situations in rodents. Single doses of OXT have also been shown to reduce predator fear.29,30 Notably, after being defeated in dominance interactions, rats display social avoidance, but not after administration of OXT.31 OXT acts on a localized population of OXT receptors in the amygdala to reduce fear behaviors.32,33 OXT also modulates activity within the hypothalamic-pituitary-adrenal (HPA) axis,34 augmenting HPA-axis activation immediately after stress exposure. This arguably facilitates system adaptation, and subsequently enhances the suppression of the HPA axis, which helps in the re-establishment of system homeostasis. T also has multiple controls over the HPA axis; T can inhibit the HPA axis at the hypothalamic, pituitary, and adrenal levels. Thus, OXT and T not only have numerous anxiolytic/fear reducing actions, especially in the social domain,35,36 but also have powerful control over HPA function and activity, particularly during stress.

The evidence for anxiolytic and fear-reducing effects of OXT and T in humans is based upon recent studies with single intranasal administrations of OXT and single sublingual administrations of T.37 Using a placebo-controlled single testosterone administration method developed for human females with an uniquely established quantity and time course of effect (the Tuiten method38), the fear and stress-reducing properties of the steroid hormone testosterone in humans have been demonstrated repeatedly by van Honk and colleagues.39–41

Early human data on the relation between testosterone, fear, and anxiety predominantly involved questionnaires that index the conscious appraisal of anxious mood. However, testosterone does not acutely act on such emotions, but only on genuine fear behaviors. Indeed, in the absence of any effects on anxiety, van Honk et al.39 showed significant reductions in vigilant responses to masked facial fear

Figure 1. The interaction between genetics and early trauma leads to hormonal changes, which in turn influence social anxiety symptoms. Here we hypothesize that hormonal treatments and psychosocial interventions, alone or in combination, may be able to be employed, perhaps in a personalized way, to reduce such symptoms. OXT, oxytocin; T, testosterone
after testosterone administration. Hermans et al. showed reductions in skin conductance and startle modulation in response to stress-inducing negative and threatening pictures in anxiety-prone participants.

Facial anger: social avoidance and social approach

Angry facial expressions are thought to have evolved in primates with a key function being social threat signaling in dominance encounters. In face-to-face challenges between primates, an enduring angry gaze signals dominance, while eye or gaze aversion signals submission. High levels of testosterone relate to social dominance in numerous species including humans. Indeed, using an adapted emotional Stroop task it was shown that vigilant responses (enduring gazes) to angry facial expressions are positively related to testosterone levels in both males and females. In these findings saliva measures were used, and so causality is not demonstrated. However, with a placebo controlled testosterone administration design (the Tuiten method), it was shown that T induces cardiac acceleration to exclusively angry faces in healthy women, indicating that the hormone plays a causal role in encourages dominance behavior. Furthermore, using the same method and testing subjects in a social approach-avoidance task, Enter et al. showed reductions in avoidant responses to facial anger, suggesting that T counteracts submissive responses of eye and gaze aversion to facial anger. This findings is relevant to SAD, because socially anxious subjects are strongly avoidant to facial anger in the same social approach-avoidance task. Terburg et al. developed an eye-tracking paradigm to measure true gaze aversion and staring endurance in unconscious face-to-face confrontations, with backwardly masked angry faces. Backward masking is a phenomenon wherein the presentation of a target stimulus (here the angry face) is immediately followed (in this case 30 milliseconds), by a masking stimulus with the same visual information but scrambled, which results in a failure to consciously perceive the target stimulus.

With this paradigm it was shown that on the dominance-submissive spectrum, relatively high dominance traits predict a prolonged gaze to masked facial anger (enduring gaze), while relatively low dominance traits predict gaze aversion. Crucially, Terburg et al. next used acute T administration and showed that individual response patterns shifted from gaze aversion to staring endurance. That is, T induced prolonged gaze to unseen angry faces. T thus seems to lead to social dominance in humans (and likely also in other mammals and in reptiles) implicitly and nonconsciously.

On the other hand, with their social approach-avoidance task, which operates at more explicit, conscious levels of processing, Radke and coworkers not only showed that avoidant response to angry facial expressions are positively related to social anxiety levels, but also that T reduced this socially avoidant behavior. Taken together, corresponding to the effects on baseline anxiety and cue-specific fear, T and OXT seem to influence dominance-submissive behaviors at different levels of processing. T operates on the most implicit non-conscious level of processing while OXT also acts on automatic behaviors but only at higher, more explicit, levels of information processing.

Furthermore, it has repeatedly been shown that OXT improves or increases the processing of happy facial expressions. These facial expressions of happiness are social reward cues, and invite social interaction. These data are consistent with findings that intranasal OXT generally leads to increased attention to the eyes of others both in experimental and realistic conditions.

Interestingly, T and OXT may act in opposite ways in the case of facial happiness, as the happy face is also an appeasement signal. T may lead to social approaches in the context of competition eg, for dominance, but not in other situations. Indeed, evidence suggests that T negatively influences the processing of happy facial expressions. In contrast, OXT seems to make social interactions in general more rewarding, and the hormone therefore enhances the processing of facial happiness. In sum, OXT may increase attention to, and memory for, positive facial expressions, because the hormone increases the rewarding properties of social interactions. T especially induces vigilant attention and responsivity to angry facial expressions, because the angry face functions as a dominance signal in face-to-face interactions, thus social dominance is at stake and the hormone is on its guard.
Toward a personalized approach

Overall, OXT reduces background anxiety, and improves the recognition of, and attention to, positive facial expression. OXT also increases attention to the eye region of the face, a sign of interest in social others, and of the willingness to socialize. Thus, the social peptide OXT seem to hold properties that make social interaction more rewarding. The social steroid T on the other hand reduces cue-specific and social fear, and submissiveness and facilitates vigilance and social approach but exclusively in competitive conditions: to compete, approach and defend status in social interactions. Anxiety, social fear and avoidance, and impaired social reward processing all are behavioral hallmarks of SAD, but the specific actions of OXT and T may suggest a personalized approach to their use in therapeutic interventions.

That is, individuals suffering from SAD and a lack of motivation to socialize may show a response to OXT, while socially fearful, submissive SAD subjects who are eager to interact may show a response to T. Importantly, as is clear from the earlier discussion, a range of validated behavioral, neuropsychological, and psycho-physiological paradigms are available to assess putative behavioral differences in SAD.

It is important to note that the effects of OXT and T may depend upon various personal and situational factors. This represents another potential opportunity; that is, for employing OXT and T administration in synergy with exposure to social experiences as part of an innovative combined treatment strategy in SAD. To date, however, research with intranasal OXT in SAD is still scarce, and published research in SAD with T administration is nonexistent.

One trial with intranasal OXT adjunctive to exposure therapy in SAD showed improvement in the mental representation of the self. Further, two pharmacological neuroimaging studies in patients with SAD receiving intranasal OXT and placebo showed attenuation of amygdala activity to fear, and the modulation of medial frontal hyperactivity to sad faces. Taken together these preliminary data are promising and provide a foundation for additional research on OXT administration in SAD.

Conclusion

The modern behavioral and psychophysiological paradigms tapping into social fearfulness, social avoidance, submissiveness, and social reward processing discussed above may be particularly useful in further investigations of the assessment and treatment of SAD. Research on OXT and T has suggested that these hormones alter such paradigms in overlapping but distinct ways. Future research on pathogenesis may usefully focus on identifying subtypes of SAD which respond differentially to OXT and T administration. Ultimately, a better understanding of OXT and T, as well as the pathogenesis of SAD may lead to interventional research which optimally integrates psychotherapy with adjunctive hormone administration.

Acknowledgments: The work in this paper was supported by funding of the South African National Research Foundation, Netherlands Society of Scientific Research, and the Medical Research Council of South Africa.

REFERENCES

1. Stein MB, Stein DJ. Social anxiety disorder. Lancet. 2008;371(9618):1115-1125.
2. Stein DJ, Ruscio AM, Lee S, et al. Subtyping social anxiety disorder in developed and developing countries. Depress Anxiety. 2010;27(4):390-403.
3. Fox NA, Henderson HA, Marshall PJ, Nichols KE, Ghera MM. Behavioral inhibition: linking biology and behavior within a developmental framework. Annu Rev Psychol. 2005;56:235-262.
4. Stein DJ, Bouwer C. Blushing and social phobia: a neuroethological speculation. Med Hypotheses. 1997;49(1):101-108.
5. Gilbert P. Evolution and social anxiety. The role of attraction, social competition, and social hierarchies. Psychiatr Clin North Am. 2001;24(4):723-751.
6. Van Honk J, Schutter DJG. Testosterone reduces conscious detection of signals serving social correction: implications for antisocial behavior. Psychol Sci. 2007;18(8):663-667.
7. Mazur A, Booth A. Testosterone and dominance in men. Behav Brain Sci. 1998;21(3):353-397.
8. Timmer M, Cordero MI, Sevelinges Y, Sandi C. Evidence for a role of oxytocin receptors in the long-term establishment of dominance hierarchies. Neuropsychopharmacology. 2011;36(11):2349-2356.
9. Gesquiere LR, Learn NH, Simaon MCM, Onyango PO, Alberts SC, Altman J. Life at the top: rank and stress in wild male baboons. Science. 2011;333(6040):357-360.
10. Van Honk J, Terburg D, Bos PA. Further notes on testosterone as a social hormone. Trends Cogn Sci. 2011;15(7):291-292.
11. Van Honk J, Schutter DJ, Bos PA, Kruijt A-W, Lentjes EG, Baron-Cohen S. Testosterone administration improves "mind-reading" in humans. Biol Psychiatry. 2007;61(6):731-733.
12. Hoge EA, Pollack MH, Kaufman RE, Zak PJ, Simon NM. Oxytocin levels in social anxiety disorder. CNS Neurosci Ther. 2008;14(3):165-170.
13. Giltay EJ, Enter D, Zitman FG, et al. Salivary testosterone: associations with depression, anxiety disorders, and antidepressant use in a large cohort study. J Psychosom Res. 2012;72(3):205-213.
Translational research

Modelos neuroendocrinos del trastorno de ansiedad social

El trastorno de ansiedad social (TAS) es una patología altamente prevalente e incapacitante con características conductuales fundamentales de temor social, evitación social y sumisión. En este artículo se argumenta que el sistema hormonal juega un papel clave en la ansiedad social y esto puede ser importante en el TAS. Las alteraciones hormonales, a menudo establecidas precozmente durante el desarrollo a través de la interacción entre los factores biológicos y psicológicos (por ej. predisposición genética y trauma precoz), predisponen al temor social, la evitación y la conducta sumisa. Sin embargo, mientras persisten las variantes genéticas y las historias de traumas, los sistemas hormonales pueden ser remodelados a lo largo de la vida. Las hormonas juegan un papel clave durante todos los periodos de ventanas sensibles del desarrollo (es decir, prenatal, neonatal, puberal y envejecimiento) y son capaces de abrir nuevas ventanas del desarrollo en la adultez. De hecho, la plasticidad del desarrollo de nuestro cerebro social y por lo tanto de la conducta social en la adultez, depende de manera fundamental de las hormonas esteroidales como la testosterona y de péptidos hormonales como la oxitocina. Esto es fundamental de las hormonas esteroidales como la testosterona y de péptidos hormonales como la oxitocina. Estos esteroides y péptidos hormonales en interacción con las experiencias sociales pueden tener el potencial para reprogramar el cerebro socialmente ansioso. Por cierto, las administraciones unicas de oxitocina y testosterona en humanos reducen el temor social y las conductas de evitación y sumisión. Este trabajo en último término puede conducir a nuevos enfoques para el tratamiento del TAS.

20. 2001;1(4):371-381.
21. 2008;11(11):1237-1334.
22. 2006;50(4):539-549.
23. 2008;62(4):247-260.
24. 2004;78(3):473-481.
25. 2005;25(39):9010-9016.
26. 2005;30(4):333-340.
27. 2008;11(11):1327-1334.
28. 2005;29(7):1089-1105.
29. 2008;4:16074-16079.
30. 2008;62(4):247-260.
31. 2001;108(38):1089-1105.
32. 2003;27:568-583.
33. 2004;8(4):321-323.
34. 2002;82(4):448-460.
35. 2002;42(4):421-428.
36. 2000;14:371-381.
37. 2005;25(39):9010-9016.
38. 2005;30(4):333-340.
39. 2010;31(4):736-756.
40. 2000;8(4):321-323.
41. 2003;27:568-583.
42. 2002;42(4):448-460.
43. 2005;25(39):9010-9016.
44. 2005;30(4):333-340.
45. 2004;78(3):473-481.
46. 2005;25(39):9010-9016.
47. 2005;25(39):9010-9016.
29. Febo M, Shields J, Ferris CF, King JA. Oxytocin modulates unconditioned fear response in lactating dams: an fMRI study. Brain Res. 2009;1302:183-193.
30. Braila D, Donzelli A, Martucci R, et al. Neurohypophyseal hormones manipulation modulate social and anxiety-related behavior in zebrafish. Psychopharmacology (Berl). 2012;220:319-330.
31. Lukas M, Toth I, Reber SO, Slattery DA, Veenema AH, Neumann ID. The neuropeptide oxytocin facilitates pro-social behavior and prevents social avoidance in rats and mice. Neuropsychopharmacology. 2011;36:2159-2168.
32. Viviani D, Charlet A, van den Burg E, et al. Oxytocin selectively gates fear responses through distinct outputs from the central amygdala. Science. 2011;333(6038):104-107.
33. Knobloch HS, Charlet A, Hoffmann LC, et al. Evoked axonal oxytocin release in the central amygdala attenuates fear response. Neuron. 2012;73(3):553-566.
34. Cohen H, Kaplan Z, Kozlovsky N, Gidon Y, Matar MA, Zohar J. Hippocampal microinfusion of oxytocin attenuates the behavioural response to stress by means of dynamic interplay with the glucocorticoid-catecho-lamine responses. J Neuroendocrinol. 2010;22(8):889-904.
35. Boissy A, Bouissou MF. Effects of androgen treatment on behavioral and physiological responses of hikers to fear-eliciting situations. Horm Behav. 1994;28(1):66-83.
36. Vandenheede M, Bouissou MF. Effect of androgen treatment on fear reactions in ewes. Horm Behav. 1993;27(4):435-448.
37. Bos PA, Panksepp J, Bluths R-M, van Honk J. Acute effects of steroid hormones and neuropeptides on human social-emotional behavior: a review of single administration studies. Front Neuroendocrinol. 2012;33(1):17-35.
38. Tuiten A, Van Honk J, Koppeschaar H, Bernaards C, Thijsen J, Ver-baten R. Time course of effects of testosterone administration on sexual arousal in women. Arch Gen Psychiatry. 2000;57(2):149-153; discussion 155-156.
39. Van Honk J, Peper JS, Schutter DJLG. Testosterone reduces unconscious fear but not consciously experienced anxiety: implications for the disorders of fear and anxiety. Biol Psychiatry. 2005;58(3):218-225.
40. Hermans EJ, Putman P, Baas JM, Koppeschaar HP, van Honk J. A single administration of testosterone reduces fear-potentiated startle in humans. Biol Psychiatry. 2006;59(9):872-874.
41. Hermans EJ, Putman P, Baas JM, Geeks NM, Kenemans JL, van Honk J. Exogenous testosterone attenuates the integrated central stress response in healthy young women. Psychoneuroendocrinology. 2007;32(8-10):1052-61.
42. Ohman A. Face the beast and fear the face: animal and social fears as prototypes for evolutionary analyses of emotion. Psychophysiology. 1986;23(2):123-145.
43. Van Honk J, Tuiten A, Verbaten R, et al. Correlations among salivary testosterone, mood, and selective attention to threat in humans. Horm Behav. 1999;36(1):17-24.
44. Van Honk J, Tuiten A, Hermans E, et al. A single administration of testoste-ron induces cardiac accelerative responses to angry faces in healthy young women. Behav Neurosci. 2001;115(1):238-242.
45. Enter D, Spinhoen P, Roelefs K. Allleviating social avoidance: effects of single dose testosterone administration on approach-avoidance action. Horm Behav. 2014;65(4):351-354.
46. Roelefs K, Putman P, Schouten S, Lange W-G, Volman I, Rinck M. Gaze direction differentially affects avoidance tendencies to happy and angry faces in socially anxious individuals. Behav Res Ther. 2010;48(4):290-294.
47. Terburg D, Hooveld N, Aarts H, Kenemans JL, van Honk J. Eye tracking unconscious face-to-face confrontations: dominance motives prolong gaze to masked angry faces. Psychol Sci. 2011;22(3):314-319.
48. Terburg D, Aarts H, van Honk J. Testosterone affects gaze aver-sion from angry faces outside of conscious awareness. Psychol Sci. 2012;23(5):459-463.
49. Radke S, Roelefs K, de Bruijn ERA. Acting on anger: social anxiety modulates approach-avoidance tendencies after oxytocin administration. Psychol Sci. 2013;24(8):1573-1578.
50. Marsh AA, Yu HH, Pine DS, Blair JR. Oxytocin improves specific recognition of positive facial expressions. Psychopharmacology (Berl). 2010;209(3):225-232.
51. Syal S, Ipser J, Terburg D, et al. Improved memory for reward cues following acute buprenorphine administration in humans. Psychoneuroen-dercrinology. 2015;53:10-15.
52. Domes G, Sibold M, Schulze L, Lischke A, Herpertz SC, Heinrichs M. Intranasal oxytocin increases covert attention to positive social cues. Psy-chol Med. 2013;43(8):1747-1753.
53. Guastella AJ, Mitchell PB, Dadds MR. Oxytocin increases gaze to the eye region of human faces. Biol Psychiatry. 2008;63(1):3-5.
54. Auyeung B, Lombardo M V, Heinrichs M, et al. Oxytocin increases eye contact during a real-time, naturalistic social interaction in males with and without autism. Transl Psychiatry. 2015;5:e507.
55. Cashdan E. Hormones, sex, and status in women. Horm Behav. 1995;29(3):354-366.
56. Dabbs JM. Testosterone, smiling, and facial appearance. J Nonverbal Behav. 1997;21(1):45-55.
57. Ramos L, Hicks C, Caminer A, Goodwin J, McGregor IS. Oxytocin and MDMA (‘Ecstasy’) enhance social reward in rats. Psychopharmacology (Berl). 2015;232(14):2631-2641.
58. Bos P a, van Honk J, Ramsey NF, Stein DJ, Hermans EJ. Testosterone administration in women increases amygdala responses to fearful and happy faces. Psychoneuroendocrinology. 2013;38(6):808-817.
59. Bartz JA, Zaki J, Bolger N, Ochsner KN. Social effects of oxytocin in humans: context and person matter. Trends Cogn Sci. 2011;15(7):301-309.
60. Guastella AJ, Howard AL, Dadds MR, Mitchell P, Carson DS. A random-ized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology. 2009;34(8):917-923.
61. Labuschagne I, Phan KL, Wood A, et al. Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder. Neuropsychopharmacology. 2010;35(12):2403-2413.
62. Labuschagne I, Phan KL, Wood A, et al. Medial frontal hyperactivity to sad faces in generalized social anxiety disorder and modulation by oxyt-ocin. Int J Neuropsychopharmacol. 2011;1-14.